Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 206 entries
Sorted by: Best Match Show Resources per page
Synthesis and comparative anion binding profiles of two di-aqua Eu(III) complexes.

Dalton transactions (Cambridge, England : 2003)

Imperio D, Giovenzana GB, Law GL, Parker D, Walton JW.
PMID: 20848045
Dalton Trans. 2010 Nov 07;39(41):9897-903. doi: 10.1039/c0dt00773k. Epub 2010 Sep 17.

Two di-aqua Eu(iii) complexes of heptadentate ligands are reported that show differing reactivity profiles towards various anions; a cationic complex with two azaxanthone moieties exhibits pronounced selectivity towards bicarbonate with an affinity constant, logK = 2.65 (295 K, 0.1...

Cite
Imperio D, Giovenzana GB, Law GL, et al. Synthesis and comparative anion binding profiles of two di-aqua Eu(III) complexes. Dalton Trans. 2010;39(41):9897-903doi: 10.1039/c0dt00773k.
Imperio, D., Giovenzana, G. B., Law, G. L., Parker, D., & Walton, J. W. (2010). Synthesis and comparative anion binding profiles of two di-aqua Eu(III) complexes. Dalton transactions (Cambridge, England : 2003), 39(41), 9897-903. https://doi.org/10.1039/c0dt00773k
Imperio, Daniela, et al. "Synthesis and comparative anion binding profiles of two di-aqua Eu(III) complexes." Dalton transactions (Cambridge, England : 2003) vol. 39,41 (2010): 9897-903. doi: https://doi.org/10.1039/c0dt00773k
Imperio D, Giovenzana GB, Law GL, Parker D, Walton JW. Synthesis and comparative anion binding profiles of two di-aqua Eu(III) complexes. Dalton Trans. 2010 Nov 07;39(41):9897-903. doi: 10.1039/c0dt00773k. Epub 2010 Sep 17. PMID: 20848045.
Copy Download .nbib Format: NLM
Massage in dermatology.

Concours medical

MEYER J, PLAS G.
PMID: 18151268
Concours Med. 1949 Jun 11;71(24):1403-5.

No abstract available.

Cite
MEYER J, PLAS G. Le massage en dermatologie. Massage in dermatology. Concours Med. 1949;71(24):1403-5
MEYER, J., & PLAS, G. (1949). Le massage en dermatologie. Massage in dermatology. Concours medical, 71(24), 1403-5.
MEYER, J, and PLAS, G. "Le massage en dermatologie." Massage in dermatology. Concours medical vol. 71,24 (1949): 1403-5.
MEYER J, PLAS G. Le massage en dermatologie. Massage in dermatology. Concours Med. 1949 Jun 11;71(24):1403-5. French. PMID: 18151268.
Copy Download .nbib Format: NLM
A highly selective on-off-on responsive lanthanide(iii) based probe for recognition of copper and hydrogen sulfide.

Dalton transactions (Cambridge, England : 2003)

Yip YW, Law GL, Wong WT.
PMID: 26584271
Dalton Trans. 2016 Jan 21;45(3):928-35. doi: 10.1039/c5dt03627e.

The development of a europium(iii) based probe (EuL1) for the detection of Cu(ii) ions and hydrogen sulphide is presented. With the addition of Cu(ii) ions, EuL1 displayed the greatest quenching among the other cations examined. The binding constant was...

Cite
Yip YW, Law GL, Wong WT. A highly selective on-off-on responsive lanthanide(iii) based probe for recognition of copper and hydrogen sulfide. Dalton Trans. 2016;45(3):928-35doi: 10.1039/c5dt03627e.
Yip, Y. W., Law, G. L., & Wong, W. T. (2016). A highly selective on-off-on responsive lanthanide(iii) based probe for recognition of copper and hydrogen sulfide. Dalton transactions (Cambridge, England : 2003), 45(3), 928-35. https://doi.org/10.1039/c5dt03627e
Yip, Yuk-Wang, et al. "A highly selective on-off-on responsive lanthanide(iii) based probe for recognition of copper and hydrogen sulfide." Dalton transactions (Cambridge, England : 2003) vol. 45,3 (2016): 928-35. doi: https://doi.org/10.1039/c5dt03627e
Yip YW, Law GL, Wong WT. A highly selective on-off-on responsive lanthanide(iii) based probe for recognition of copper and hydrogen sulfide. Dalton Trans. 2016 Jan 21;45(3):928-35. doi: 10.1039/c5dt03627e. PMID: 26584271.
Copy Download .nbib Format: NLM
Confocal laser endomicroscopy to guide sampling of a pure ground-glass opacity.

ERJ open research

Viatgé T, Villeneuve T, D'Aure D, Mazières J, Plat G, Hermant C, Guibert N.
PMID: 33834056
ERJ Open Res. 2021 Apr 06;7(2). doi: 10.1183/23120541.00910-2020. eCollection 2021 Apr.

No abstract available.

Cite
Viatgé T, Villeneuve T, D'Aure D, et al. Confocal laser endomicroscopy to guide sampling of a pure ground-glass opacity. ERJ Open Res. 2021;7(2)doi: 10.1183/23120541.00910-2020.
Viatgé, T., Villeneuve, T., D'Aure, D., Mazières, J., Plat, G., Hermant, C., & Guibert, N. (2021). Confocal laser endomicroscopy to guide sampling of a pure ground-glass opacity. ERJ open research, 7(2), . https://doi.org/10.1183/23120541.00910-2020
Viatgé, Thibault, et al. "Confocal laser endomicroscopy to guide sampling of a pure ground-glass opacity." ERJ open research vol. 7,2 (2021). doi: https://doi.org/10.1183/23120541.00910-2020
Viatgé T, Villeneuve T, D'Aure D, Mazières J, Plat G, Hermant C, Guibert N. Confocal laser endomicroscopy to guide sampling of a pure ground-glass opacity. ERJ Open Res. 2021 Apr 06;7(2). doi: 10.1183/23120541.00910-2020. eCollection 2021 Apr. PMID: 33834056; PMCID: PMC8021808.
Copy Download .nbib Format: NLM
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.

BMJ (Clinical research ed.)

Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD.
PMID: 34933868
BMJ. 2021 Dec 21;375:e066381. doi: 10.1136/bmj-2021-066381.

OBJECTIVE: To evaluate pathological complete response as a surrogate endpoint for disease-free survival and overall survival in regulatory neoadjuvant trials of early stage breast cancer.DESIGN: Systematic review and meta-analysis.DATA SOURCES: Medline, Embase, and Scopus to 1 December 2020.ELIGIBILITY CRITERIA...

Cite
Conforti F, Pala L, Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381doi: 10.1136/bmj-2021-066381.
Conforti, F., Pala, L., Sala, I., Oriecuia, C., De Pas, T., Specchia, C., Graffeo, R., Pagan, E., Queirolo, P., Pennacchioli, E., Colleoni, M., Viale, G., Bagnardi, V., & Gelber, R. D. (2021). Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ (Clinical research ed.), 375e066381. https://doi.org/10.1136/bmj-2021-066381
Conforti, Fabio, et al. "Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis." BMJ (Clinical research ed.) vol. 375 (2021): e066381. doi: https://doi.org/10.1136/bmj-2021-066381
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021 Dec 21;375:e066381. doi: 10.1136/bmj-2021-066381. PMID: 34933868.
Copy Download .nbib Format: NLM
A smart "off-on" gate for the .

Chemical science

Liang Z, Tsoi TH, Chan CF, Dai L, Wu Y, Du G, Zhu L, Lee CS, Wong WT, Law GL, Wong KL.
PMID: 29899943
Chem Sci. 2016 Mar 01;7(3):2151-2156. doi: 10.1039/c5sc04091d. Epub 2015 Dec 07.

A water-soluble and emissive Eu-complex (

Cite
Liang Z, Tsoi TH, Chan CF, et al. A smart "off-on" gate for the . Chem Sci. 2015;7(3):2151-2156doi: 10.1039/c5sc04091d.
Liang, Z., Tsoi, T. H., Chan, C. F., Dai, L., Wu, Y., Du, G., Zhu, L., Lee, C. S., Wong, W. T., Law, G. L., & Wong, K. L. (2016). A smart "off-on" gate for the . Chemical science, 7(3), 2151-2156. https://doi.org/10.1039/c5sc04091d
Liang, Zhenhao, et al. "A smart "off-on" gate for the ." Chemical science vol. 7,3 (2016): 2151-2156. doi: https://doi.org/10.1039/c5sc04091d
Liang Z, Tsoi TH, Chan CF, Dai L, Wu Y, Du G, Zhu L, Lee CS, Wong WT, Law GL, Wong KL. A smart "off-on" gate for the . Chem Sci. 2016 Mar 01;7(3):2151-2156. doi: 10.1039/c5sc04091d. Epub 2015 Dec 07. PMID: 29899943; PMCID: PMC5968757.
Copy Download .nbib Format: NLM
Periodontitis predicts HbA1c levels and glucose variability in type 1 diabetic patients: the PARODIA Florence Project study.

Clinical oral investigations

Cairo F, Dicembrini I, Serni L, Nieri M, Bettarini G, Caliri M, Pala L, Mannucci E, Barbato L.
PMID: 35031877
Clin Oral Investig. 2022 Jan 15; doi: 10.1007/s00784-021-04326-4. Epub 2022 Jan 15.

OBJECTIVE: The aim of the present study was to assess the extent and severity of periodontal disease among type 1 diabetic patients (T1DM) and to investigate the possible association with systemic markers of glucose control and variability.MATERIAL AND METHODS:...

Cite
Cairo F, Dicembrini I, Serni L, et al. Periodontitis predicts HbA1c levels and glucose variability in type 1 diabetic patients: the PARODIA Florence Project study. Clin Oral Investig. 2022;doi: 10.1007/s00784-021-04326-4.
Cairo, F., Dicembrini, I., Serni, L., Nieri, M., Bettarini, G., Caliri, M., Pala, L., Mannucci, E., & Barbato, L. (2022). Periodontitis predicts HbA1c levels and glucose variability in type 1 diabetic patients: the PARODIA Florence Project study. Clinical oral investigations, . https://doi.org/10.1007/s00784-021-04326-4
Cairo, Francesco, et al. "Periodontitis predicts HbA1c levels and glucose variability in type 1 diabetic patients: the PARODIA Florence Project study." Clinical oral investigations vol. (2022). doi: https://doi.org/10.1007/s00784-021-04326-4
Cairo F, Dicembrini I, Serni L, Nieri M, Bettarini G, Caliri M, Pala L, Mannucci E, Barbato L. Periodontitis predicts HbA1c levels and glucose variability in type 1 diabetic patients: the PARODIA Florence Project study. Clin Oral Investig. 2022 Jan 15; doi: 10.1007/s00784-021-04326-4. Epub 2022 Jan 15. PMID: 35031877.
Copy Download .nbib Format: NLM
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML.

Cancers

Millot F, Suttorp M, Ragot S, Leverger G, Dalle JH, Thomas C, Cheikh N, Nelken B, Poirée M, Plat G, Versluys B, Lausen B, Borisevich M.
PMID: 34439257
Cancers (Basel). 2021 Aug 15;13(16). doi: 10.3390/cancers13164102.

Within the International Registry of Childhood Chronic Myeloid Leukemia (CML), we identified 18 patients less than 18 years old at diagnosis of CML who were in the chronic phase and exhibiting a sustained deep molecular response (DMR) to imatinib...

Cite
Millot F, Suttorp M, Ragot S, et al. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML. Cancers (Basel). 2021;13(16)doi: 10.3390/cancers13164102.
Millot, F., Suttorp, M., Ragot, S., Leverger, G., Dalle, J. H., Thomas, C., Cheikh, N., Nelken, B., Poirée, M., Plat, G., Versluys, B., Lausen, B., & Borisevich, M. (2021). Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML. Cancers, 13(16), . https://doi.org/10.3390/cancers13164102
Millot, Frédéric, et al. "Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML." Cancers vol. 13,16 (2021). doi: https://doi.org/10.3390/cancers13164102
Millot F, Suttorp M, Ragot S, Leverger G, Dalle JH, Thomas C, Cheikh N, Nelken B, Poirée M, Plat G, Versluys B, Lausen B, Borisevich M. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML. Cancers (Basel). 2021 Aug 15;13(16). doi: 10.3390/cancers13164102. PMID: 34439257; PMCID: PMC8392145.
Copy Download .nbib Format: NLM
EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials.

JNCI cancer spectrum

Conforti F, Pala L, Bagnardi V, Specchia C, Oriecuia C, Marra A, Zagami P, Morganti S, Tarantino P, Catania C, De Marinis F, Queirolo P, De Pas T.
PMID: 33344882
JNCI Cancer Spectr. 2020 Jul 29;4(6):pkaa064. doi: 10.1093/jncics/pkaa064. eCollection 2020 Dec.

BACKGROUND: Results of several randomized clinical trials (RCTs) testing the combination of an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) plus an anti-angiogenic drug in advanced EGFR-mutated non-small cell lung cancer were reported.METHODS: We first report a systematic...

Cite
Conforti F, Pala L, Bagnardi V, et al. EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectr. 2020;4(6):pkaa064doi: 10.1093/jncics/pkaa064.
Conforti, F., Pala, L., Bagnardi, V., Specchia, C., Oriecuia, C., Marra, A., Zagami, P., Morganti, S., Tarantino, P., Catania, C., De Marinis, F., Queirolo, P., & De Pas, T. (2020). EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI cancer spectrum, 4(6), pkaa064. https://doi.org/10.1093/jncics/pkaa064
Conforti, Fabio, et al. "EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials." JNCI cancer spectrum vol. 4,6 (2020): pkaa064. doi: https://doi.org/10.1093/jncics/pkaa064
Conforti F, Pala L, Bagnardi V, Specchia C, Oriecuia C, Marra A, Zagami P, Morganti S, Tarantino P, Catania C, De Marinis F, Queirolo P, De Pas T. EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectr. 2020 Jul 29;4(6):pkaa064. doi: 10.1093/jncics/pkaa064. eCollection 2020 Dec. PMID: 33344882; PMCID: PMC7737478.
Copy Download .nbib Format: NLM
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.

BMJ (Clinical research ed.)

Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD.
PMID: 34933868
BMJ. 2021 Dec 21;375:e066381. doi: 10.1136/bmj-2021-066381.

OBJECTIVE: To evaluate pathological complete response as a surrogate endpoint for disease-free survival and overall survival in regulatory neoadjuvant trials of early stage breast cancer.DESIGN: Systematic review and meta-analysis.DATA SOURCES: Medline, Embase, and Scopus to 1 December 2020.ELIGIBILITY CRITERIA...

Cite
Conforti F, Pala L, Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381doi: 10.1136/bmj-2021-066381.
Conforti, F., Pala, L., Sala, I., Oriecuia, C., De Pas, T., Specchia, C., Graffeo, R., Pagan, E., Queirolo, P., Pennacchioli, E., Colleoni, M., Viale, G., Bagnardi, V., & Gelber, R. D. (2021). Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ (Clinical research ed.), 375e066381. https://doi.org/10.1136/bmj-2021-066381
Conforti, Fabio, et al. "Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis." BMJ (Clinical research ed.) vol. 375 (2021): e066381. doi: https://doi.org/10.1136/bmj-2021-066381
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021 Dec 21;375:e066381. doi: 10.1136/bmj-2021-066381. PMID: 34933868.
Copy Download .nbib Format: NLM
Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy.

European journal of cancer (Oxford, England : 1990)

Repetto M, Conforti F, Pirola S, Calvello M, Pala L, Bonanni B, Catania C, Curigliano G, De Pas T.
PMID: 34161910
Eur J Cancer. 2021 Aug;153:162-167. doi: 10.1016/j.ejca.2021.05.029. Epub 2021 Jun 20.

IMPORTANCE: Thymic carcinoma (TC) is a rare aggressive tumour occurring in adults characterised by one of the lowest tumor mutational burdens (TMB). Microsatellite instability (MSI) is a mutational signature, caused by defects in the DNA MisMatch Repair (MMR) system,...

Cite
Repetto M, Conforti F, Pirola S, et al. Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. Eur J Cancer. 2021;153:162-167doi: 10.1016/j.ejca.2021.05.029.
Repetto, M., Conforti, F., Pirola, S., Calvello, M., Pala, L., Bonanni, B., Catania, C., Curigliano, G., & De Pas, T. (2021). Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. European journal of cancer (Oxford, England : 1990), 153162-167. https://doi.org/10.1016/j.ejca.2021.05.029
Repetto, M, et al. "Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy." European journal of cancer (Oxford, England : 1990) vol. 153 (2021): 162-167. doi: https://doi.org/10.1016/j.ejca.2021.05.029
Repetto M, Conforti F, Pirola S, Calvello M, Pala L, Bonanni B, Catania C, Curigliano G, De Pas T. Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. Eur J Cancer. 2021 Aug;153:162-167. doi: 10.1016/j.ejca.2021.05.029. Epub 2021 Jun 20. PMID: 34161910.
Copy Download .nbib Format: NLM
Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.

Pediatric blood & cancer

Aubert L, Petit A, Bertrand Y, Ray-Lunven AF, Angoso M, Pluchart C, Millot F, Saultier P, Cheikh N, Pellier I, Plantaz D, Sirvent A, Thouvenin-Doublet S, Valduga J, Plat G, Rialland F, Henry C, Esvan M, Gandemer V.
PMID: 34854546
Pediatr Blood Cancer. 2021 Dec 02;e29441. doi: 10.1002/pbc.29441. Epub 2021 Dec 02.

BACKGROUND: Since the introduction of tyrosine kinase inhibitors (TKIs), the profile of pediatric relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia (PhPROCEDURE: We retrospectively analyzed the therapeutic strategies and outcomes of pediatric PhRESULTS: Twenty-seven children experienced a PhCONCLUSION: We show...

Cite
Aubert L, Petit A, Bertrand Y, et al. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study. Pediatr Blood Cancer. 2021;e29441doi: 10.1002/pbc.29441.
Aubert, L., Petit, A., Bertrand, Y., Ray-Lunven, A. F., Angoso, M., Pluchart, C., Millot, F., Saultier, P., Cheikh, N., Pellier, I., Plantaz, D., Sirvent, A., Thouvenin-Doublet, S., Valduga, J., Plat, G., Rialland, F., Henry, C., Esvan, M., & Gandemer, V. (2021). Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study. Pediatric blood & cancer, e29441. https://doi.org/10.1002/pbc.29441
Aubert, Lucie, et al. "Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study." Pediatric blood & cancer vol. (2021): e29441. doi: https://doi.org/10.1002/pbc.29441
Aubert L, Petit A, Bertrand Y, Ray-Lunven AF, Angoso M, Pluchart C, Millot F, Saultier P, Cheikh N, Pellier I, Plantaz D, Sirvent A, Thouvenin-Doublet S, Valduga J, Plat G, Rialland F, Henry C, Esvan M, Gandemer V. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study. Pediatr Blood Cancer. 2021 Dec 02;e29441. doi: 10.1002/pbc.29441. Epub 2021 Dec 02. PMID: 34854546.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 206 entries